Brief: Evotec And Sernova Announce Exclusive Strategic Partnership For IPSC-Based Beta Cell Replacement Therapy
17/05/2022 06:34
May 17 (Reuters) - EVOTEC SE EVTG.DE :
* EVOTEC AND SERNOVA ANNOUNCE EXCLUSIVE STRATEGIC
PARTNERSHIP FOR
IPSC-BASED BETA CELL REPLACEMENT THERAPY TO ADVANCE A
'FUNCTIONAL CURE' FOR DIABETES
* MAKES STRATEGIC EUR 20 M EQUITY INVESTMENT IN SERNOVA
Source text for Eikon: ID:nEQ6hZ1Gba
Further company coverage: EVTG.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Sernova Biotherapeutics
See all newsBrief: Seraxis And Sernova Announce Appointment Of Former FDA Medical Officer Dr. Patricia Beaston As Chief Medical Officer Of Seraxis And Post Merger Betanova Biotherapeutics
Brief: Sernova Appoints Jonathan Rigby As Interim Chair
Brief: Sernova Biotherapeutics Provides Positive Interim Data From Ongoing Phase 1/2 Clinical Trial Of Cell Pouch Bio-Hybrid Organ In Patients Living With Type 1 Diabetes
Brief: Sernova Biotherapeutics Secures $4 Million Loan To Further Advance Its Clinical Development Plans
Brief: Sernova Biotherapeutics Inc Study Is On Track To Meet Key Clinical Trial Endpoints